Lipoprotein-associated phospholipase A2, C-reactive protein, and coronary artery disease in individuals with type 1 diabetes and macroalbuminuria

Diabetes and Vascular Disease Research

Volumn 7, Issue 1, 2010, Pages 47-55

  Miller, Rachel G ^a   Costacou, Tina ^a   Orchard, Trevor J ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

C reactive protein; Coronary artery disease; Haptoglobin genotype; Lp PLA2; Macroalbuminuria; Type I diabetes

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; C REACTIVE PROTEIN; HAPTOGLOBIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ADULT; ALBUMINURIA; ARTICLE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; QUESTIONNAIRE;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; ALBUMINURIA; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 1; FEMALE; GENOTYPE; HAPTOGLOBINS; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; YOUNG ADULT;

EID: 77949404323     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.1177/1479164109346358     Document Type: Article

References (58)

1. Ross R (1999) Atherosclerosis: an inflammatory disease. N Engl J Med 340: 115-126.
2. McPhee CH, Moores KE, Boyd HF, et al. (1999) Lipoprotein- associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 338: 479-487.
3. Snyder F (1995) Platelet-activating factor and its analogs: metabolic pathways and related intracellular processes. Biochim Biophys Acta 1254: 231-249.
4. Häkkinen T, Luoma JS, Hiltunen MO, et al. (1999) Lipoprotein- associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol 19: 2909-2917.
5. Carpenter KL, Dennis IF, Challis IR, et al. (2001) Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocytemacrophages. FEBS Lett 50: 357-363.
6. Tjoelker LW, Wilder C, Eberhardt C, et al. (1995) Antiinflammatory properties of a platelet-activating factor acetylhydrolase. Nature 374: 549-553.
7. Quarck R, De Geest B, Stengel D, et al. (2001) Adenovirusmediated gene transfer of human platelet-activating factoracetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation 103: 2495-2500.
8. Noto H, Hara M, Karasawa K, et al. (2003) Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress. Arterioscler Thromb Vasc Biol 23: 829-835.
9. Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH (2000) Lipoprotein-associated phospholipase A2, platelet-activating factor acetlyhoydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 150: 413-419.
10. Packard CJ, O'Reilly DSJ, Caslake MJ, et al. (2000) Lipoprotein- associated phospholipase A2 as an independent predictor of coronary artery disease. N Engl J Med 2000; 343: 1148-1154.
11. Koenig W, Khuseyinova N, Löwel H, Trischler G, Meisinger C (2004) Lipoprotein-associated phospholipase A2 adds to the risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 110: 1903-1908.
12. Ballantyne CM, Hoovgeveen RC, Bang H, et al. (2004) Lipoprotein- associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 109: 837-842.
13. Oei HS, van der Meer IM, Hofman A, et al. Lipoproteinassociated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 111: 570-575.
14. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB (2005) Association of Lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 26: 137-144.
15. Winkler K, Winkelmann BR, Scharnagl H, et al. Platelet- activating factor acetlyhoydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study. Circulation 111: 980-987.
16. Koenig W, Twardella D, Brenner H, Rothenbacher D. (2006) Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol 26: 1586-1593.
17. Kim JY, Hyun YJ, Jang Y, et al. (2008) Lipoprotein-associated phospholipase A2 activity is associated with coronary artery disease and markers of oxidative stress: a case-control study. Am J Clin Nutr 88: 360-367.
18. Deckert T, Poulsen JE, Larsen M. (1978) Prognosis of diabetics with diabetes onset before the age of thirty-one. II. Factors influencing the prognosis. Diabetologia 14: 371-377.
19. Christlieb AR, Warram JH, Krolewski AS, et al. (1981) Hypertension: the major risk factor in juvenile-onset insulindependent diabetics. Diabetes 30: 90-96.
20. Dorman JS, LaPorte RE, Kuller LH, et al. (1984) The Pittsburgh Insulin-Dependent Diabetes Mellitus (IDDM) Morbidity and Mortality Study: mortality results. Diabetes 33: 271-276.
21. Krolewski AS, Kosinski EJ, Warram JH, et al. (1987) Magnitude and determinants of coronary artery disease in juvenileonset, insulin-dependent diabetes mellitus. Am J Cardiol 59: 750-755.
22. Moss SE, Klein R, Klein BE (1991) Cause-specific mortality in a population-based study of diabetes. Am J Public Health 81: 1158-1162.
23. Orchard TJ, Olson JC, Erbey JR, et al. (2003) Insulin resistance- related factors, but not glycemia, predict coronary artery disease in type 1 diabetes. Diabetes Care 26: 1374-1379.
24. Soedamah-Muthu SS, Chaturvedi N, Toeller M, et al. (2004) The EURODIAB Prospective Complications Study Group: Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study. Diabetes Care 27: 530-537.
25. Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ (2006) The 30-year natural history of type 1 iabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes 55: 1463-1469.
26. Ridker PM, Hennekens CH, Buring JE, Rifai N (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342: 836-843.
27. Rohde LEP, Hennekens CH, Ridker PM (1999) Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. Am J Cardiol 84: 1018-1022.
28. Strandberg TE, Tiluis RS (2000) C-reactive protein, cardiovascular disease, and mortality in a prospective study in the elderly. Arterioscler Thromb Vasc Biol 20: 1057-1060.
29. Freeman DJ, Norrie J, Caslake MJ, et al. (2002) C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 51: 1596-1600.
30. Ridker PM, Glynn RJ, Hennekens CH (1998) C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 97: 2007-2011.
31. Danesh J, Whincup P, Walker M, et al. (2000) Low grade inflammation and coronary artery disease: prospective study and updated meta-analyses. BMJ 321: 199-204.
32. Ridker PM, Rifai N, Rose L, Burning JE, Cook NR (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 1557-1565.
33. Ridker PM (2003) Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 170: 363-369.
34. Boekholdt SM, Sandhu MS, Day NE, et al. (2006) Physical activity, C-reactive protein levels and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. Eur J Cardiovasc Prev Rehabil 13: 970-976.
35. Pu LJ, Lu L, Xu XW, et al. (2006) Value of serum glycated albumin and high-sensitivity C-reactive protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes. Cadiovasc Diabetol 5: 27.
36. Hsich MC, Tien KJ, Chang SJ, et al. (2008) High-sensitivity C-reactive protein and silent myocardial ischemia in Chinese with type 2 diabetes mellitus. Metabolism 57: 1533-1538.
37. Colhoun HM, Schalkwijk C, Rubens MB, Stehouwer CD (2002) C-reactive protein in type 1 diabetes and its relationship to coronary artery calcification. Diabetes Care 25: 1813-1817.
38. Costacou T, Zgibor JC, Evans RW, et al. (2005) The prospective association between adiponectin and coronary artery disease among individuals with type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 48: 41-48.
39. Jenkins AJ, Rothen M, Klein RL, et al. (2008) Cross-sectional associations of C-reactive protein with vascular risk factors and vascular complications in the DCCT/EDIC cohort. J Diabetes Complications 22: 153-163.
40. Levy AP, Hochberg I, Jablonski K, et al. (2002) Strong Heart Study: haptoglobin genotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study. J Am Coll Cardiol 40: 1984-1990. 41. Suleiman M, Aronson D, Asleh R, et al. (2005) Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction. Diabetes 54: 2802-2806.
41. Roguin A, Koch W, Kastrati A, Aronson D, Schomig A, Levy AP (2003) Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes. Diabetes Care 26: 2628-2631.
42. Costacou T, Ferrell RE, Orchard TJ (2008) Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetes. Diabetes 57: 1702.
43. Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR (1985) The changing natural history of nephropathy in type I diabetes. Am J Med 78: 785-794.
44. Jensen T, Borch-Johnsen K, Kofoed-Enevoldsen A, Deckert T (1987) Coronary heart disease in young type 1 (insulindependent) diabetic patients with and without nephropathy: incidence and risk factors. Diabetologia 30: 144-148.
45. Tuomilehto J, Borch-Johnsen K, Molarius A, et al. (1998) Incidence of cardiovascular disease in type 1 (insulin-dependent) diabetic subjects with and without diabetic nephropathy in Finland. Diabetologia 41: 784-790.
46. Klein BEK, Klein R, McBride PE, et al. (2004) Cardiovascular disease, mortality, and retinal microvascular characteristics in type 1 diabetes: Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Intern Med 164: 1917-1924.
47. Torffvit O, Lövestam-Adrian M, Agardh E, Agardh C-D (2005) Nephropathy, but not retinopathy, is associated with the development of heart disease in type 1 diabetes: as 12-year observation study of 462 patients. Diabet Med 22: 723-729.
48. Giunti S, Bruno G, Veglio M, et al. (2005) Electrocardiographic left ventricular hypertrophy in type 1 diabetes: prevalence and relation to coronary heart disease and the cardiovascular risk factors: the Eurodiab IDDM Complications Study. Diabetes Care 28: 2255-2257.
49. Koch W, Latz W, Eichinger M, et al. (2002) Genotyping of the common haptoglobin Hp 1/2 polymorphism based on PCR. Clin Chem 48: 1377-1382.
50. Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC (1974) Enzymatic determination of total serum cholesterol. Clin Chem 20: 470-475.
51. Bucolo G, David H (1973) Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 19: 476-482.
52. Warnick GR, Albers JJ (1978) Heparin-Mn2 1 quantitation of high-density-lipoprotein cholesterol: an ultrafiltration procedure for lipemic samples. Clin Chem 24: 900-904.
53. National Institutes of Health, Department of Health (1975) Lipid Research Clinics Program. Washington, DC: US Government Printing Office, pp 75-628
54. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502.
55. Borhani NO, Kass EH, Langford HG, Payne GH, Remington RD, Stamler J (1976) The hypertension detection and followup program. Prev Med 5: 207-215.
56. Furberg CD, Nelson JJ, Solomon CS, Cushman M, Swords JN, Psaty BM (2008) Distribution and correlates of lipoprotein- associated phospholipase A2 in an elderly cohort: the Cardiovascular Health Study. J Am Geriatr Soc 56: 792-799.
57. Allison MA, Denenberg JO, Nelson JJ, Natarajan L, Criqui MH (2007) The association between lipoprotein-associated phospholipase A2 and cardiovascular disease and total mortality in vascular medicine patients. J Vasc Surg 46: 500-506.
58. Blake GJ, Dada N, Fox JC, Manson JE, Ridker PM (2001) A prospective evaluation of lipoprotein-associated phospholipase A2 levels and the risk of future cardiovascular events in women. J Am Coll Cardiol 38: 1302-1306.